RxDoctor Payments Data

Albert Janke, DO

Cardiovascular Disease · Blue Bell, PANPI 1265437073

Payments from drug & device makers

$569in general payments, 2019–2025

Across 23 payments — averaging $24.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$122
  • Novartis$100
  • E.r. Squibb & Sons, L.L.C.$91
  • Abbott$90
  • Boehringer Ingelheim$57
  • Pfizer$47
  • plus $63 from 3 others

What the payments were for

  • Food & beverage$55798%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$569 in reported general payments places this provider in the 25th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$571,372
Medicare patients
805
Services billed
3,847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban304$374,644
XareltoRivaroxaban43$49,836
JanuviaSitagliptin Phosphate38$44,824
OzempicSemaglutide24$26,431
JardianceEmpagliflozin17$23,286
EntrestoSacubitril/Valsartan20$19,244
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide264$16,877
FarxigaDapagliflozin Propanediol12$14,656
Metoprolol Succinate752$13,508
Valsartan256$12,217
Praluent PenAlirocumab21$11,444
Rosuvastatin Calcium682$10,771
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,628
Atorvastatin Calcium441$6,582
Diltiazem 24hr Er (Cd)Diltiazem Hcl100$3,619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$47$374,644304 claims
Boehringer IngelheimJardiance$57$23,28617 claims
NovartisEntresto$100$19,24420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Blue Bell

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →